Brain scans reveal lasting tissue and chemical changes in both long COVID and recovered patients

Recent medical reports and brain scan data indicate that COVID-19 can cause lasting tissue and chemical changes in the brain. These alterations are observed not only in patients suffering from long COVID but also in those who have recovered from the initial infection. According to a report from ScienceAlert, brain scans have revealed that patients with long COVID have 18% fewer dopamine nerve endings. Further evidence of neurological impact is presented in a case report from Cureus, which highlights relative brain perfusion differences in a patient experiencing persistent vestibular symptoms and neurocognitive issues associated with the post-COVID-19 condition. Coverage of these findings is appearing across various scientific and news platforms.

PsyPost reports that the structural and chemical changes in the brain are persisting across different patient groups. Simultaneously, a Canadian study cited by the news agency SANA indicates that these COVID-19-related brain changes can persist for years after the initial illness. The collective reporting emphasizes a transition from viewing the virus as a purely respiratory threat to recognizing its long-term capacity to modify brain chemistry and tissue integrity over an extended period. The context for these findings is rooted in the ongoing study of the post-COVID-19 condition, specifically how it affects the central nervous system. The mention of dopamine nerve ending loss is particularly significant as dopamine is a key chemical for brain function.

Additionally, the Cureus case report provides a clinical look at how perfusion differences—essentially how blood flows through the brain—correlate with specific neurocognitive and vestibular symptoms, providing a physiological basis for the "brain fog" and balance issues often reported by patients. Future attention will likely focus on the duration of these changes and whether they are reversible. Because the Canadian study mentioned by SANA establishes that these alterations can last for years, monitoring the long-term trajectory of brain tissue health will be critical. Observers will be looking for further data on whether the 18% reduction in dopamine nerve endings is a universal marker for long COVID or specific to certain patient subsets, as well as more case reports on brain perfusion differences to determine if these patterns are consistent across the wider population.